ID   MOVP-3
AC   CVCL_N031
DR   cancercelllines; CVCL_N031
DR   ChEMBL-Cells; CHEMBL3307302
DR   ChEMBL-Targets; CHEMBL614133
DR   PubChem_Cell_line; CVCL_N031
DR   Wikidata; Q54906419
RX   PubMed=12623853;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C9142; Adult T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0624 ! MOLT-3
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 05-10-23; Version: 16
//
RX   PubMed=12623853; DOI=10.1182/blood-2002-07-2268;
RA   Schroeder U., Bernt K.M., Lange B., Wenkel J., Jikai J., Shabat D.,
RA   Amir R., Huebener N., Niethammer A.G., Hagemeier C., Wiebusch L.,
RA   Gaedicke G., Wrasidlo W., Reisfeld R.A., Lode H.N.;
RT   "Hydrolytically activated etoposide prodrugs inhibit MDR-1 function
RT   and eradicate established MDR-1 multidrug-resistant T-cell leukemia.";
RL   Blood 102:246-253(2003).
//